Litcius/Paper detail

Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies

Michael Tarpley, Helen Oladapo, Dillon Strepay, Thomas B. Caligan, Lhoucine Chdid, Hassan Shehata, Jose Roques, Rhashad Thomas, Christopher P. Laudeman, Rob U. Onyenwoke, David B. Darr, Kevin P. Williams

2021European Journal of Pharmaceutical Sciences44 citationsDOIOpen Access PDF

Topics & Concepts

HarmineChemistryMonoamine oxidaseMonoamine oxidase BPharmacologyMonoamine oxidase ASelegilineBiochemistryBiologyEnzymeMedicineParkinson's diseasePathologyDiseaseSynthesis and bioactivity of alkaloidsSynthesis and pharmacology of benzodiazepine derivativesCancer therapeutics and mechanisms
Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies | Litcius